These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27806324)

  • 1. PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK.
    Lu T; Zou Y; Xu G; Potter JA; Taylor GL; Duan Q; Yang Q; Xiong H; Qiu H; Ye D; Zhang P; Yu S; Yuan X; Zhu F; Wang Y; Xiong H
    Oncotarget; 2016 Dec; 7(50):83017-83030. PubMed ID: 27806324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms.
    Li XL; Zhou J; Chan ZL; Chooi JY; Chen ZR; Chng WJ
    Oncotarget; 2015 Nov; 6(34):36689-99. PubMed ID: 26452133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
    Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
    Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells.
    Yoshikawa N; Kajiyama H; Nakamura K; Utsumi F; Niimi K; Mitsui H; Sekiya R; Suzuki S; Shibata K; Callen D; Kikkawa F
    Oncol Rep; 2016 May; 35(5):2543-52. PubMed ID: 26986846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.
    Patyka M; Sharifi Z; Petrecca K; Mansure J; Jean-Claude B; Sabri S
    Oncotarget; 2016 Sep; 7(37):60245-60269. PubMed ID: 27533246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.
    Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS
    Clin Cancer Res; 2011 May; 17(9):2830-41. PubMed ID: 21415220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53.
    Sobhani M; Abdi J; Manujendra SN; Chen C; Chang H
    Cancer Biol Ther; 2015; 16(5):799-806. PubMed ID: 25803193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.
    Saha MN; Abdi J; Yang Y; Chang H
    Oncotarget; 2016 Feb; 7(6):7149-60. PubMed ID: 26771839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
    Zache N; Lambert JM; Wiman KG; Bykov VJ
    Cell Oncol; 2008; 30(5):411-8. PubMed ID: 18791272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance.
    Tessoulin B; Descamps G; Moreau P; Maïga S; Lodé L; Godon C; Marionneau-Lambot S; Oullier T; Le Gouill S; Amiot M; Pellat-Deceunynck C
    Blood; 2014 Sep; 124(10):1626-36. PubMed ID: 25006124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.
    Haagensen EJ; Thomas HD; Mudd C; Tsonou E; Wiggins CM; Maxwell RJ; Moore JD; Newell DR
    Eur J Cancer; 2016 Mar; 56():69-76. PubMed ID: 26820797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein.
    Stuber G; Flaberg E; Petranyi G; Otvös R; Rökaeus N; Kashuba E; Wiman KG; Klein G; Szekely L
    Mol Cancer; 2009 Mar; 8():23. PubMed ID: 19323829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
    Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Meher RK; Mir SA; Anisetti SS
    J Biomol Struct Dyn; 2024 May; 42(8):4169-4184. PubMed ID: 37272907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
    Saha MN; Jiang H; Yang Y; Reece D; Chang H
    Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.
    Li Y; Mao Y; Brandt-Rauf PW; Williams AC; Fine RL
    Mol Cancer Ther; 2005 Jun; 4(6):901-9. PubMed ID: 15956247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
    Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
    Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
    Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
    Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The small molecule AU14022 promotes colorectal cancer cell death via p53-mediated G2/M-phase arrest and mitochondria-mediated apoptosis.
    Ryu H; Nam KY; Kim JS; Hwang SG; Song JY; Ahn J
    J Cell Physiol; 2018 Jun; 233(6):4666-4676. PubMed ID: 29030986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.